1 recruiting, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow HR Positive: new trials by email Literature Review of HR Positive trials Research Report on HR Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 |
Breast Neoplasms (2) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Neoplasm, Residual (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Urinary Bladder Neoplasms (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adnexal Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
ALX148 (1) · Paclitaxel (1) · trastuzumab duocarmazine (1) · tucatinib (1) · zanidatamab (1)
QuantumLeap Healthcare Collaborative (2)
United States (2)